BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.89B |
| Revenue (ttm) | 2.75B |
| Net Income (ttm) | -766.00M |
| Shares Out | n/a |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 837 |
| Average Volume | 1,021 |
| Open | 93.85 |
| Previous Close | 95.95 |
| Day's Range | 90.75 - 93.85 |
| 52-Week Range | 69.70 - 124.60 |
| Beta | 1.30 |
| RSI | 42.27 |
| Earnings Date | Aug 4, 2025 |
About Exscientia
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
News
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
BioNTech Q2 2025 Earnings Preview
A Look Ahead: BioNTech's Earnings Forecast
BioNTech (NASDAQ: BNTX) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement. Analysts estimate that BioNTech will rep...
Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.This decision affirms the ...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Pfizer, BioNTech win EU backing for updated COVID shot
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8. ...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union | BNTX Stock News
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Medic...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Medici...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recomm...
8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth
The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by rising viral infections and diagnostic innovations acro...
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Add...
BioNTech chief strategy officer resigning
BioNTech Announces Ryan Richardson to Step Down from the Management Board
MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management...
BioNTech: More Uncertainty Emerges
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-run...
Family offices ramp up deal-making in June with bets on biotech
A biotech startup backed by former Google CEO Eric Schmidt raised $56 million from investors including the billionaire family office that supported BioNTech.
Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
Amarin Corporation Plc (NASDAQ: AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A. , Italy, to commercialize Vazkepa (icosapent ethyl) in 59 count...
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...